Bevacizumab in the treatment of high-grade gliomas: an overview
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Biochemistry,Physiology
Link
http://link.springer.com/content/pdf/10.1007/s10456-011-9232-2.pdf
Reference43 articles.
1. National Cancer Institute (2010) Brain tumor. National Institutes of Health. http://www.cancer.gov/cancertopics/types/brain . Accessed 8 May 2011
2. Narayana A, Recht L, Gutin PH (2010) Central nervous system tumors. In: Hoppe RT, Philips TL, Roach M (eds) Textbook of radiation oncology. Saunders, Philadelphia, pp 421–432
3. Bernstein JJ, Woodard CA (1995) Glioblastoma cells do not intravasate into blood vessels. Neurosurgery 36(1):124–132 discussion 132
4. Harper SJ, Bates DO (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8(11):880–887
5. Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L (2008) Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 68(12):4683–4692. doi: 10.1158/0008-5472.can-07-6577
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study;Journal of Clinical Neuroscience;2024-02
2. Pseudogene MAPK6P4-encoded functional peptide promotes glioblastoma vasculogenic mimicry development;Communications Biology;2023-10-18
3. Knockdown of USF1 Inhibits the Vasculogenic Mimicry of Glioma Cells via Stimulating SNHG16/miR-212-3p and linc00667/miR-429 Axis;Molecular Therapy - Nucleic Acids;2019-03
4. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy;Clinical Neurology and Neurosurgery;2018-06
5. Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review;Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics;2016-06-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3